Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-Current Assets (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Non-Current Assets for 10 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 47.74% year-over-year to $1.8 million, compared with a TTM value of $10.8 million through Sep 2025, down 90.15%, and an annual FY2024 reading of $3.3 million, down 93.62% over the prior year.
  • Non-Current Assets was $1.8 million for Q3 2025 at Spero Therapeutics, down from $2.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $51.2 million in Q4 2023 and bottomed at $1.8 million in Q3 2025.
  • Average Non-Current Assets over 5 years is $13.1 million, with a median of $11.6 million recorded in 2022.
  • The sharpest move saw Non-Current Assets skyrocketed 355.68% in 2023, then crashed 93.62% in 2024.
  • Year by year, Non-Current Assets stood at $13.2 million in 2021, then decreased by 14.91% to $11.2 million in 2022, then skyrocketed by 355.68% to $51.2 million in 2023, then plummeted by 93.62% to $3.3 million in 2024, then plummeted by 43.46% to $1.8 million in 2025.
  • Business Quant data shows Non-Current Assets for SPRO at $1.8 million in Q3 2025, $2.7 million in Q2 2025, and $3.0 million in Q1 2025.